KPV Research Guide: Structure, Mechanism, Preclinical Findings and Handling

For laboratory research use only; not for human consumption. This guide consolidates what is known about KPV as a research reagent: where the sequence comes from, how it is made and verified, what the model-system literature does and does not show, and how to handle and document the material. It is written for investigators planning bench work, not as guidance for any use outside a laboratory.

What KPV is

KPV is a linear tripeptide. Lysine carries a basic, positively charged side chain; proline is a cyclic imino acid that restricts the backbone; valine is a small hydrophobic residue at the C-terminus. Those three residues are identical to the last three residues of α-MSH, a 13-residue neuropeptide cleaved from the precursor pro-opiomelanocortin (POMC). Interest in the fragment comes from a simple observation: a very short piece of a larger signaling peptide appears to keep a defined activity in some model systems while shedding the parts of the parent that drive other receptor responses.

That makes KPV a convenient reduction experiment. Where the full α-MSH molecule engages several melanocortin receptors and has effects on pigmentation, appetite circuits and inflammation, the fragment is used to ask which behaviors travel with the terminal tripeptide alone. For a short plain-language introduction, see what is KPV peptide; for the catalog-level summary, see the KPV research overview.

Discovery and history

α-MSH was characterized long before KPV drew attention, first as the pituitary peptide that darkens amphibian skin and later as a multifunctional melanocortin. The thirteen-residue sequence is acetylated at the N-terminus and amidated at the C-terminus: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂. The core His-Phe-Arg-Trp motif in the middle of that chain is the message sequence recognized by melanocortin receptors, which is why analogs built around it, such as melanotan-II, are potent receptor agonists.

The tail is a different story. In the 1980s, work from the laboratory of James Lipton reported that the C-terminal tripeptide (residues 11-13) retained antipyretic activity in animal studies, and a 1989 report described anti-inflammatory activity of a COOH-terminal fragment of the neuropeptide. Those findings shifted attention from the receptor-binding core to the terminal residues, and they established the logic still used today: a fragment that lacks the His-Phe-Arg-Trp message sequence cannot behave like a conventional melanocortin agonist, so any activity it retains is likely to follow a different route. A 2008 review by Brzoska and colleagues gathered the biochemistry and the in vitro and in vivo anti-inflammatory evidence for α-MSH and its related tripeptides, and remains the standard entry point to this literature.

A second thread of the history is practical. Three-residue peptides are cheap to make and easy to verify, so KPV became a durable reagent that laboratories could revisit across different models. It also became a building block: the same motif is fused to a copper-binding sequence in GHK-KPV, a hybrid studied as a two-motif chain. The comparison between the isolated fragment and its parent is developed further in KPV vs α-MSH: a melanocortin comparison, and the narrative version is in KPV discovery and history.

Chemical structure and synthesis

The three residues each contribute something different to the physicochemical fingerprint of the molecule. Lysine supplies the only side-chain charge and a primary amine that is a typical site for conjugation chemistry. Proline's ring locks the backbone dihedral angle and prevents the peptide bond preceding it from adopting the usual trans-only geometry in an unconstrained way, so the molecule has less conformational freedom than three arbitrary residues would. Valine adds a compact isopropyl side chain and sets the hydrophobic end of the molecule. General principles for reading such sequences are covered in understanding amino acid sequences.

Research KPV is made by solid-phase peptide synthesis: the chain is assembled from the C-terminal valine on a resin, one protected amino acid at a time, then cleaved, deprotected and purified. Only three coupling and deprotection cycles are needed, so the typical truncation and deletion byproducts that complicate longer chains are minimal. The main synthesis-related impurities for a tripeptide are different in kind: incompletely removed protecting groups, diketopiperazine formation involving the N-terminal dipeptide (Lys-Pro is a classic diketopiperazine-prone pair), racemization at a residue, and residual counter-ions from purification. Because the whole molecule is only about 342 Da, a small absolute amount of impurity is a large fraction of a test article, which is why identity and purity documentation matters more than the size of the peptide would suggest.

After purification the peptide is lyophilized (what is lyophilization) and checked by reversed-phase HPLC for purity and by mass spectrometry for identity. The expected monoisotopic and average masses are easy to confirm, and a mass shift of 18 Da or a missing residue is obvious. The chemistry is summarized in KPV structure and synthesis.

Mechanism of action

The mechanism of KPV is best described as a set of hypotheses with varying degrees of support, and it helps to separate them.

It lacks the melanocortin message sequence

Melanocortin receptors (MC1R through MC5R) recognize the His-Phe-Arg-Trp core of α-MSH. KPV does not contain it. In receptor assays this means little or no classic agonism, which is why the fragment is treated as a cleaner probe for non-pigmentary biology than the parent peptide. Some groups have nonetheless reported effects that depend on melanocortin receptor expression in specific cell types, so the statement that KPV is receptor-independent should be read as a working hypothesis, not a settled fact. Where a study's conclusion depends on receptor involvement, the right controls are receptor-selective antagonists and cell lines with defined receptor expression.

Intracellular entry and signaling

The leading hypothesis is that KPV acts after entering cells. A widely cited 2008 study by Dalmasso and colleagues reported that KPV is taken up through the peptide transporter PepT1, which is expressed in intestinal epithelium and can be induced in inflamed tissue, and that intracellular KPV reduced pro-inflammatory signaling, including NF-κB and MAP-kinase activation, in cell and mouse colitis models. That finding is the origin of the idea that a tripeptide may reach intracellular targets through a transporter that handles di- and tripeptides. It also implies that transporter expression in the chosen model determines whether the peptide gets in at all, a variable worth measuring.

Interpreting a mechanism in practice

Three physical features argue for an intracellular, signal-modulating hypothesis rather than a surface-receptor one: the peptide is tiny, it lacks a large binding surface, and its chemistry is dominated by one charge, one rigid residue and one hydrophobic residue. None of this identifies a molecular target. A claim about mechanism should therefore be tied to the assay: which cells, which stimulus, which readout, what concentration and how long. The sequence of events (uptake, pathway inhibition, change in cytokine output) should be demonstrated rather than inferred, ideally with a transporter-blocking condition and an inactive sequence-matched comparator. The mechanistic reading of the literature is expanded in KPV mechanism of action.

Preclinical research findings

Preclinical work with KPV centers on inflammation models, mostly epithelial or immune cell cultures stimulated with a pro-inflammatory agent, and on rodent models of intestinal inflammation. Because the peptide is small and chemically simple, it fits well into controlled, concentration-defined experiments. The table summarizes the model types in the literature and the readouts each is used for; it describes what the model is designed to show, not outcomes outside the laboratory.

Two points deserve emphasis. First, fragment-focused studies are strongest when KPV is run side by side with the parent sequence, a scrambled or inactive tripeptide, and a vehicle control; otherwise an effect cannot be attributed to the specific sequence. Second, cell viability and nonspecific assay interference must be separated from pathway-specific readouts. A peptide at a high concentration can change medium conditions or cell health and look like pathway inhibition. Reporting the model, stimulus, concentration range and exposure time in detail is what makes a result reproducible. Further notes are in KPV preclinical research, and a mechanistic comparison with other catalog peptides is in KPV vs other research peptides.

Handling, reconstitution and storage

KPV is hydrophilic and small, so it dissolves almost immediately in water-based diluents. The practical hazard is quantitation: a few milligrams of a 342 Da lyophilized cake can look like almost nothing in a vial, and the concentration of the stock depends entirely on the volume of diluent actually added. Record the volume, not the appearance. The general procedure is the same as for any lyophilized peptide: let the vial reach room temperature before opening, use sterile technique, add the diluent slowly down the inside wall of the vial rather than onto the cake, and mix by gentle swirling without vortexing. The full technique is described in the lyophilized peptide reconstitution guide, and the compound-specific notes are in KPV reconstitution and storage. Bacteriostatic water is the usual diluent for a multi-use stock; sterile water is preferred when the stock will be aliquoted at once or used in cell culture where benzyl alcohol could interfere.

The concentration formula is simple: mg of peptide in the vial divided by mL of diluent added gives mg/mL. The reconstitution calculator performs the same arithmetic for any vial size. The table converts common stock concentrations to molar units using 342.4 g/mol; for exact molar work, multiply by the net peptide content and purity stated on the certificate of analysis, because lyophilized peptides also contain counter-ions and residual moisture.

For storage, the lyophilized powder is the most stable form and should be kept cold, dry and protected from light. Tripeptides lack the secondary structure that makes larger peptides prone to aggregation, so physical instability is rarely the concern; chemical stability in solution over weeks is the more relevant question. Single-use aliquots, labeled with concentration and date, avoid repeated freeze-thaw cycles, and a conservative window of about 28 days at 2-8 °C is the usual convention for a preserved multi-use vial. These durations are laboratory conventions rather than validated shelf lives for a given lot. General cold-chain principles are covered in storing research peptides.

Purity, COA and quality

For a molecule this small, quality documentation is the main control on whether an experiment means anything. A lot-specific certificate of analysis should show, at minimum, the HPLC purity with the chromatogram itself (not only a summary percentage), a mass-spectrometry result consistent with about 342.4 Da, the lot number matching the vial, and the date of testing. HPLC and mass spectrometry answer different questions: chromatography estimates how much of the material elutes as the main species, while mass spectrometry shows whether that species has the expected mass. The distinction is explained in understanding HPLC purity and how to read a COA.

Certificates for current lots are collected on the COA page, and KPV-specific analytical notes, including how identity is confirmed, are in KPV purity testing and identity verification. The product listing is KPV; sourcing and documentation questions are addressed in where to buy KPV research peptide.

Related compounds and comparisons

KPV is easiest to understand next to its relatives. Against α-MSH it is a minimal fragment: three residues instead of thirteen, with no His-Phe-Arg-Trp core. Against melanotan-II, a cyclic analog built around that core, it is close to the opposite design choice, since melanotan-II keeps and strengthens the receptor-recognition motif while KPV keeps only the tail. A third relative, PT-141, is derived from the same melanocortin scaffold as melanotan-II but studied for a more MC4R-focused profile. These pairings let investigators choose a comparator that isolates one variable at a time.

The head-to-head treatments are in KPV vs α-MSH and KPV vs other research peptides. For the hybrid, see the GHK-KPV research overview.

Frequently asked questions

What is KPV?

KPV is the tripeptide lysine-proline-valine, corresponding to residues 11-13 at the C-terminus of α-MSH. It is used as a research reagent in studies of inflammation-related signaling in cell and animal models.

Is KPV a melanocortin receptor agonist?

Not in the classic sense. It lacks the His-Phe-Arg-Trp message sequence that melanocortin receptors recognize, so it is treated as a probe for non-pigmentary activity. Some reports describe receptor-dependent effects in particular cell types, so this should be tested rather than assumed in each model.

How does KPV enter cells?

A 2008 study by Dalmasso and colleagues reported uptake through the peptide transporter PepT1 in intestinal epithelial cells. Because transporter expression varies between cell types, uptake should be verified in the model being used.

What is the molecular weight of KPV?

About 342.4 g/mol (formula C16H30N4O4). A certificate of analysis for a correct lot should show a mass-spectrometry result consistent with this value.

Why is quality documentation so important for a three-residue peptide?

Because the molecule is so small, a modest absolute amount of impurity is a large fraction of the test article. Chromatogram, observed mass and net peptide content together define what was actually added to an assay.

How do I calculate stock concentration?

Divide the milligrams of peptide in the vial by the milliliters of diluent added. A 10 mg vial in 2 mL gives 5 mg/mL, about 14.6 mM at 342.4 g/mol. The calculator on this site gives the same result for any vial size.

Which diluent should I use?

Bacteriostatic water suits a multi-use refrigerated stock. Sterile water is better for stocks that will be aliquoted at once or used in cell culture where benzyl alcohol could interfere; include a vehicle control either way.

How should KPV be stored?

Keep the lyophilized powder cold, dry and protected from light. After reconstitution, use single-use aliquots to avoid repeated freeze-thaw, and regard roughly 28 days at 2-8 °C as a conservative convention for a preserved vial, not a validated shelf life.

How does KPV differ from GHK-KPV?

KPV is the isolated tripeptide. GHK-KPV is a hybrid chain that fuses KPV to a copper-binding GHK motif, so it carries two motifs in one molecule and has different chemistry and handling.

Can results from cell models be extended to other settings?

No. Findings describe the behavior of the tested model under defined conditions. Species, cell type, transporter expression, concentration and stimulus all affect the outcome, and conclusions should stay proportional to what the experiment measured.

Responsible research use

KPV is a small, well-defined fragment, and its value to a laboratory is the same as its simplicity: a known sequence, a known mass and a clear comparison to its parent peptide. That value is only realized when the material is verified, the controls are complete and the interpretation stays within what the model shows. Document the lot, the preparation and the storage history alongside every result so that other laboratories can reproduce it. Read the certificate of analysis before the first experiment, and keep the reconstitution volume in the notebook.

For laboratory research use only; not for human consumption. Nothing in this guide describes use in people or animals outside controlled research settings.

References

1. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602.
2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
3. Richards DB, Lipton JM. Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit. Peptides. 1984;5(4):815-817.
4. Hiltz ME, Lipton JM. Anti-inflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-2284.